Focusing on ‘Scheduled Drug – Processes and Complications in Global Logistics’, PCI’s Rich Nelson, Senior Manager, Global Logistics for Clinical Services, will prese...

CAR-T treatments for blood cancer are often given on an inpatient basis so patients can be monitored for dangerous side effects. University of Southern California r...

An experimental drug for a rare lung condition has failed in a registrational trial, prompting its manufacturer, United Therapeutics, to halt further development....

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of th...

Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by dela...

Alnylam on Friday released full results from a pivotal Phase 3 study for givosiran, setting the stage for the company to finish a U.S. regulatory application in t...

Clovis Oncology's PARP inhibitor Rubraca fell short in its monotherapy bladder cancer test, but it's on track for a first-in-class approval in prostate cancer. (Clo...